Biomedical Engineering Reference
In-Depth Information
23. Cuzick J, Sestak I, Baum M,
Effect of anastrozole and tamoxifen as
adjuvant treatment for early-stage breast cancer: 10-year analysis of
the ATAC trial.
et al.
Lancet Oncol
11: 1135-1141, 2010.
24. Dowsett M, Cuzick J, Wale C,
Prediction of risk of distant recurrence
using the 21-gene recurrence score in node-negative and node-positive
postmenopausal patients with breast cancer treated with anastrozole
or tamoxifen: a TransATAC study.
et al.
J Clin Oncol
28: 1829-1834.
25. Olivotto IA, Bajdik CD, Ravdin PM,
Population-based validation of
the prognostic model ADJUVANT! for early breast cancer.
et al.
J Clin Oncol
23: 2716-2725, 2005.
26. Goldstein LJ, O'Neill A, Sparano JA,
Concurrent doxorubicin plus
docetaxel is not more effective than concurrent doxorubicin plus
cyclophosphamide in operable breast cancer with 0 to 3 positive
axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
J Clin Oncol
et al.
26: 4092-4099, 2008.
27. Goldstein LJ, Gray R, Badve S,
Prognostic utility of the 21-gene
assay in hormone receptor-positive operable breast cancer compared
with classical clinicopathologic features.
et al.
J Clin Oncol
26: 4063-4071,
2008.
28. Oratz R, Paul D, Cohn AL,
Impact of a commercial reference
laboratory test recurrence score on decision making in early-stage
breast cancer.
et al.
3: 182-186, 2007.
29. Lo SS, Mumby PB, Norton J,
J Oncol Pract
Prospective multicenter study of the
impact of the 21-gene recurrence score assay on medical oncologist
and patient adjuvant breast cancer treatment selection.
et al.
J Clin Oncol
28:
1671-1676, 2010.
30. Oratz R, Kim B, Chao C,
Physician survey of the effect of the 21-
gene recurrence score assay results on treatment recommendations
for patients with lymph node-positive, estrogen receptor-positive
breast cancer.
et al.
7: 94-99, 2011.
31. Marchionni L, Wilson RF, Wolff AC,
J Oncol Pract
Systematic review: gene
expression profiling assays in early-stage breast cancer.
et al.
Ann Intern
148: 358-369, 2008.
32. Evaluation of Genomic Applications in Practice and Prevention
(EGAPP) Working Group. Recommendations from the EGAPP Working
Group: can tumor gene expression profiling improve outcomes in
patients with breast cancer?
Med
Genet Med
11: 66-73, 2009.
33. Harris L, Fritsche H, Mennel R,
American Society of Clinical
Oncology 2007 update of recommendations for the use of tumor
markers in breast cancer.
et al.
J Clin Oncol
25: 5287-5312, 2007.
